Geovax Labs Keeps 'Buy' Rating with $9 Price Target

Geovax Labs (GOVX) maintains a "Buy" rating and price target of $9.00 USD from D. Boral Capital's analyst Jason Kolbert. The company's strong position in the market is reflected in the consistent rating and unchanged price target. The average one-year price target from 5 analysts is $10.70, with an upside of 1,356.77% from the current price. The average brokerage recommendation is 2.0, indicating an "Outperform" status.

Title: GeoVax Labs (GOVX): Analysts Maintain Positive Outlook Despite Recent Stock Performance

July 2, 2025 - Despite recent fluctuations in its stock price, GeoVax Labs (GOVX) continues to attract positive analyst ratings. D. Boral Capital's analyst Jason Kolbert maintains a "Buy" rating and a price target of $9.00 USD for the company. This consistent rating reflects GeoVax Labs' strong market position and potential for growth.

The average one-year price target from five analysts stands at $10.70, indicating an impressive upside potential of 1,356.77% from the current price. The average brokerage recommendation is 2.0, which translates to an "Outperform" status. This consensus suggests that analysts believe in the company's long-term prospects.

However, recent market performance has shown mixed signals. According to a technical analysis report [1], GOVX has several negative signals and is within a falling trend, making it a "Strong Sell" candidate. The stock price ended at $0.7345 on July 16, 2025, after rising 6.38% from $0.6958. The technical indicators lean more towards a neutral outlook in the mid-term.

GeoVax Labs' recent focus on accelerating the development of its GEO-MVA vaccine candidate, supported by the European Medicines Agency's streamlined development pathway, is expected to bolster its market position. The company is actively engaging with global health authorities to expand access to its Mpox vaccine candidate, addressing the growing urgency of global outbreaks [2].

Despite the recent stock performance, analysts remain optimistic about GeoVax Labs' future. The company's strong IP portfolio and lead clinical programs, including its GEO-CM04S1 vaccine and Gedeptin® oncolytic therapy, position it as a key player in the biotechnology sector.

References:
[1] https://intellectia.ai/stock/GOVX/forecast
[2] https://www.nasdaq.com/press-release/geovax-highlights-growing-urgency-diversified-mpox-vaccine-supply-global-outbreaks